RedHill's Opaganib Shows Positive Preclinical Results in Neuroblastoma and Triple-Negative Breast Cancer
RDHL sits 21% above its 52-week low of $0.71.
Summary
RedHill Biopharma announced positive preclinical data for its drug candidate Opaganib in neuroblastoma and triple-negative breast cancer, suggesting enhanced chemotherapy efficacy and anti-tumor immunity.
Key Events · Product Development and Regulatory · RDHL
-
Positive Preclinical Data
Opaganib showed positive effects as an add-on therapy in models of neuroblastoma (NB) and triple-negative breast cancer (TNBC) at the AACR 2026 Annual Meeting.
-
Enhanced Chemotherapy Efficacy
In neuroblastoma, Opaganib enhanced the therapeutic efficacy of the oxaliplatin + doxorubicin chemotherapy combination by directly destabilizing n-Myc.
-
Augmented Anti-Tumor Immunity
In triple-negative breast cancer, Opaganib pre-treatment potentiated STING-mediated effects, potentially augmenting anti-tumor immunity.
-
Orphan Drug Designation
Opaganib holds FDA Orphan Drug and Rare Pediatric Disease designations for the treatment of neuroblastoma.
Analysis · RDHL · Life Sciences
This filing provides positive preclinical data for Opaganib, a key pipeline asset, in two difficult-to-treat cancers. While preclinical, these results offer a potential long-term value driver and a positive development amidst the company's recent Nasdaq delisting notice. The data suggests Opaganib could enhance chemotherapy efficacy and augment anti-tumor immunity, supporting its continued development and potential for an Orphan Drug Priority Review Voucher.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RDHL was trading at $0.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.71 to $3.31. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.